Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/LBL
Phase 1
Recruiting
- Conditions
- Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
- Interventions
- Biological: CD5-targeted CAR-T cells
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT06874946
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
Effects of Barley Green on Visceral Fat Area in the Human Body and Investigation Into the Associated Mechanism of Intestinal Microbiota
Not Applicable
Recruiting
- Conditions
- People With High Body Fat PercentagePeople With High Visceral Fat Area
- First Posted Date
- 2025-03-20
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 66
- Registration Number
- NCT06886048
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Xicheng District, China
Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL
Phase 1
Recruiting
- Conditions
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
- Interventions
- Biological: Nanobody-Based CD19/CD22 Tandem Dual CAR-T
- First Posted Date
- 2025-03-18
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT06880913
- Locations
- 🇨🇳
Deparment of Hematology, Peking University People's Hospital, Beijing, Beijing, China
KPD Consolidation After ASCT in NDMM Patients
Phase 2
Recruiting
- Conditions
- Multiple Myeloma, Newly Diagnosed
- Interventions
- Drug: KPD (carfilzomib, pomalidomide, and dexamethasone) consolidation
- First Posted Date
- 2025-03-17
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 202
- Registration Number
- NCT06879379
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
🇨🇳Fuxing Hospital affiliated to Capital Medical University, Beijing, Beijing, China
🇨🇳Shanghai Changzheng Hospital, Shanghai, Shanghai, China
Clinical Effect Observation of Barley Green Intervention in Hyperuricemia Population and Related Mechanism Study of Xanthine Oxidase
Not Applicable
Completed
- Conditions
- Hyperuricemia
- First Posted Date
- 2025-03-14
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 96
- Registration Number
- NCT06876909
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Xicheng District, China
Efficacy, Safety and Immunological Evaluation of Upadacitinib for Relapsing Polychondritis
Phase 1
Recruiting
- Conditions
- Relapsing Polychondritis
- Interventions
- Drug: corticosteroids and immunosuppressants
- First Posted Date
- 2025-03-12
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT06873100
- Locations
- 🇨🇳
Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, Beijing, China
Thiotepa Combined With Busulfan and Fludarabine Conditioning Regimen for Haploidentical Hematopoietic Stem Cell Transplantation in Elderly Patients With High-Risk Acute Myeloid Leukemia
Phase 2
Recruiting
- Conditions
- Acute Myeloid Leukemia (AML)High Risk Acute Myeloid Leukemia(AML)Relapsed/Refractory Acute Myeloid Leukemia (AML)
- Interventions
- Drug: Thiotepa ;busulfan;fludarabine
- First Posted Date
- 2025-03-11
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 56
- Registration Number
- NCT06869265
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
The Application of Novel Identified CD8 Regulatory Precursors in Inducing Immune Tolerance After Allo-HSCT
- Conditions
- Graft-versus-host Disease (GVHD)
- First Posted Date
- 2025-03-07
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT06864598
- Locations
- 🇨🇳
No. 11 Xizhimen South Street, Xicheng District, Beijing, China, Beijing, Beijing, China
Therapeutic Effect of Upadacitinib in Primary Sjögren's Syndrome
Phase 2
Not yet recruiting
- Conditions
- Primary Sjögren's Syndrome (pSS)
- Interventions
- First Posted Date
- 2025-03-06
- Last Posted Date
- 2025-03-11
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT06862284
- Locations
- 🇨🇳
Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China
Exploring the Expression Level of Cadherin 6 Protein (CDH6) in Primary Malignant Bone Tumor Specimens and Its Clinical Application in Prognosis Assessment
Active, not recruiting
- Conditions
- SarcomaSarcoma, BoneEwing SarcomaOsteosarcoma
- First Posted Date
- 2025-02-27
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 70
- Registration Number
- NCT06850506
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
© Copyright 2025. All Rights Reserved by MedPath